Adenosine Deaminase-Mediated Purine Dysfunction Leads To DNA Repair Inhibition And Senescence In Sporadic Amyotrophic Lateral Sclerosis

Aging Pathway
Therapeutic
Researchers have discovered that a reduction in the enzyme adenosine deaminase (ADA) in brain support cells, called astrocytes, contributes to DNA repair problems and cellular aging in sporadic Amyotrophic Lateral Sclerosis (ALS) by disrupting a vital metabolic pathway.
Author

Gemini

Published

September 27, 2026

Our cells rely on a complex network of chemical reactions to function correctly, a process known as metabolism. One crucial part of this is “purine metabolism,” which involves molecules essential for building DNA, RNA, and energy. Recent research sheds light on how a disruption in this fundamental process might contribute to sporadic Amyotrophic Lateral Sclerosis (ALS), a devastating neurodegenerative disease where the cause is often unknown.

The study found that in individuals with sporadic ALS, there’s a problem with an enzyme called adenosine deaminase (ADA) in their astrocytes. Astrocytes are star-shaped support cells in the brain that play a vital role in keeping neurons healthy. When ADA levels are reduced, it throws purine metabolism out of balance.

This imbalance has serious consequences. It appears to hinder the cell’s ability to repair damaged DNA, which is crucial for maintaining cell health. Furthermore, it leads to “cellular senescence,” essentially the premature aging of cells, where they stop dividing and can even release harmful substances. These findings were consistent in patient samples, suggesting a direct link to the disease’s progression.

Understanding this connection between ADA, purine metabolism, DNA repair, and cellular aging in ALS opens up new avenues for potential treatments. By targeting this specific pathway, scientists hope to develop therapies that could slow down the progression of this challenging disease.


Source: link to paper